medimix.be
Oct 10, 2024, 06:38
Guilherme Nader Marta: The impact of low levels of HER2 expression in the Ph3 PALLAS trial
Clinical Fellow at Dana-Farber Cancer Institute, recently shared about the Ph3 PALLAS trial. Read his post on LinkedIn below:
”Proud to share our study looking at the impact of low levels of HER2 expression (HER2-low) in the Ph3 PALLAS trial, including data from >5,300 patients with early ER+ breast cancer enrolled globally.
Geographic variability in HER2-low prevalence was seen across continents, with North America (63%) showing higher rates than Europe and other regions (53%).
This variability extended across countries (17-76%) and even between different sites within a single country. No significant difference in outcomes or palbociclib benefit between patients with HER2-low and HER2-0 tumors.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 12, 2024, 23:10
Nov 12, 2024, 23:07
Nov 12, 2024, 22:58
Nov 12, 2024, 22:56
Nov 12, 2024, 22:50
Nov 12, 2024, 22:46
Nov 12, 2024, 22:43